Completed
Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients
What is being tested
Levcromakalim
+ Saline
Drug
Who is being recruted
Brain Diseases+9
+ Central Nervous System Diseases
+ Epilepsy
From 18 to 60 Years
+7 Eligibility Criteria
How is the trial designed
Other Study
Placebo-Controlled
Interventional
Study Start: July 2019
Summary
Principal SponsorDanish Headache Center
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: July 9, 2019
Actual date on which the first participant was enrolled.To investigate the role of KATP channels in migraine with aura patients.
Official TitleHeadache Inducing Effect of Levcromakalim in Migraine With Aura Patients
Principal SponsorDanish Headache Center
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
17 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other Study
Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Brain DiseasesCentral Nervous System DiseasesEpilepsyHeadacheMigraine DisordersNervous System DiseasesNeurologic ManifestationsPainSigns and SymptomsPathological Conditions, Signs and SymptomsHeadache DisordersHeadache Disorders, Primary
Criteria
3 inclusion criteria required to participate
Migraine with aura patients of both sexes.
18-60 years.
50-100 kg.
4 exclusion criteria prevent from participating
Headache less than 48 hours before the tests start
Daily consumption of drugs of any kind other than oral contraceptives
Pregnant or nursing women.
Cardiovascular disease of any kind, including cerebrovascular diseases.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center